Vibe Bioscience Ltd (VIBE) AI Stock Analysis

Vibe Bioscience Ltd

(CNQX:VIBE)

Select Model

Rating:50Neutral

Price Target:CAD 0.50▼(-20.63% Downside)

Action:reiterated

Date:10/07/26

The score is held down primarily by elevated financial risk—negative equity and continued net losses—despite improving operations and positive free cash flow. Technicals are supportive in the near term (price above major moving averages and positive MACD), but extremely overbought momentum signals increase the risk of a short-term reversal. Valuation is constrained by negative earnings and the absence of dividend yield data.

Positive Factors

Revenue and operating reboundThe latest period shows a meaningful operating recovery, with revenue growth accompanied by positive EBIT and EBITDA margins. If this improvement persists, it could strengthen internal funding capacity, support reinvestment, and improve the company’s ability to build more durable earnings power.

Negative Factors

Negative shareholders’ equityNegative equity materially limits financial flexibility and indicates that the company’s accumulated financial position remains weak. It can increase dependence on external funding, raise dilution or refinancing risk, and restrict the resources available to absorb setbacks or finance growth.

Vibe Bioscience Ltd (VIBE) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 680.21K
Dividend Yield: ―
Average Volume (3M): 1,781
Price to Earnings (P/E): -0.2
Beta (1Y): 2.41
Revenue Growth: 24.29%
EPS Growth: 41.04%
Country: Canada
Employees: 165
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Vibe Bioscience Ltd Business Overview & Revenue Model

Company Description

Vibe Growth Corp. is a vertically integrated cannabis company. The firm operates retail dispensaries, cannabis greenhouse and indoor cultivation, commercial distribution and transportation, e-commerce and home delivery, and manufacturing of marijuana...

Vibe Bioscience Ltd Financial Statement Overview

Summary

Operations are improving (TTM revenue +12.5% and EBIT/EBITDA margins turning positive) and cash generation is now positive (TTM operating cash flow and free cash flow). However, the balance sheet is a major risk with negative equity in the latest periods, and the company remains unprofitable at the net income level (TTM net margin about -15%) with a history of large losses.

Income Statement

46Neutral

Balance Sheet

28Negative

Cash Flow

55Neutral

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	20.44M	17.53M	12.71M	14.15M	20.71M	29.29M
Gross Profit	7.99M	6.95M	4.74M	5.17M	6.49M	8.42M
EBITDA	1.26M	1.43M	-3.91M	-8.42M	-3.14M	-1.11M
Net Income	-3.10M	-2.45M	-6.54M	-11.13M	-9.45M	-4.30M
Balance Sheet
Total Assets	15.94M	10.95M	11.29M	16.28M	25.89M	32.90M
Cash, Cash Equivalents and Short-Term Investments	1.19M	753.51K	1.06M	1.17M	4.55M	9.10M
Total Debt	3.26M	2.46M	2.57M	2.89M	3.38M	2.83M
Total Liabilities	28.15M	18.58M	16.51M	15.20M	13.63M	11.50M
Stockholders Equity	-12.21M	-7.63M	-5.22M	1.08M	12.26M	21.39M
Cash Flow
Free Cash Flow	475.19K	17.18K	202.82K	-2.78M	-3.71M	-7.20M
Operating Cash Flow	538.97K	63.61K	233.74K	-2.71M	-1.97M	848.73K
Investing Cash Flow	-63.78K	-46.43K	19.02K	-71.80K	-1.75M	-8.43M
Financing Cash Flow	-392.84K	-334.53K	-360.37K	-595.55K	-699.14K	14.33M

Vibe Bioscience Ltd Technical Analysis

Technical Analysis SentimentPositive

Last Price0.63

Price Trends

50DMA0.51Positive

100DMA0.47Positive

200DMA0.46Positive

Market Momentum

MACD0.04Positive

RSI67.73Neutral

STOCH0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VIBE, the sentiment is Positive. The current price of 0.63 is above the 20-day moving average (MA) of 0.60, above the 50-day MA of 0.51, and above the 200-day MA of 0.46, indicating a bullish trend. The MACD of 0.04 indicates Positive momentum. The RSI at 67.73 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:VIBE.

Vibe Bioscience Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TSE:VIBE against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:VIBE	50Neutral	CAD 680.21K	-0.16	36.21%	―	24.29%	41.04%
TSE:XBRA	49Neutral	CAD 420.72K	-0.14	-610.58%	―	―	―

* Healthcare Sector Average

Performance Comparison

TSE:VIBE and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:VIBE	Vibe Bioscience	0.63	-0.12	-16.00%
TSE:MLCL	Molecule Holdings Inc.	0.01	0.00	0.00%
TSE:GHG	Global Hemp	0.02	0.00	0.00%
TSE:XBRA	Xebra Brands Ltd.	0.01	0.00	0.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 07, 2026

Vibe Bioscience Ltd AI Stock Analysis